TG Therapeutics (NASDAQ:TGTX) has been given a $27.00 price target by equities researchers at LADENBURG THALM/SH SH in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. LADENBURG THALM/SH SH’s price objective would suggest a potential upside of 373.68% from the company’s current price.

Several other research analysts have also issued reports on TGTX. ValuEngine lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. BidaskClub lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, June 12th. Zacks Investment Research raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 26th. HC Wainwright reissued a “buy” rating and set a $38.00 target price on shares of TG Therapeutics in a research note on Tuesday, August 7th. Finally, Raymond James lowered shares of TG Therapeutics from a “strong-buy” rating to an “outperform” rating and cut their target price for the stock from $22.00 to $12.00 in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. TG Therapeutics currently has an average rating of “Hold” and a consensus price target of $26.40.

Shares of NASDAQ TGTX opened at $5.70 on Wednesday. The firm has a market cap of $426.52 million, a P/E ratio of -2.98 and a beta of 1.16. TG Therapeutics has a 12-month low of $4.95 and a 12-month high of $17.35.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.04). The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 177.79% and a negative net margin of 97,412.51%. analysts predict that TG Therapeutics will post -2.19 EPS for the current year.

In other TG Therapeutics news, CFO Sean A. Power sold 47,191 shares of the company’s stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $13.21, for a total transaction of $623,393.11. Following the transaction, the chief financial officer now owns 473,267 shares in the company, valued at $6,251,857.07. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 15.10% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its holdings in TG Therapeutics by 12.7% during the first quarter. Wells Fargo & Company MN now owns 39,535 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 4,460 shares during the last quarter. Highland Capital Management LP raised its holdings in TG Therapeutics by 1.0% during the second quarter. Highland Capital Management LP now owns 469,241 shares of the biopharmaceutical company’s stock worth $6,171,000 after buying an additional 4,850 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in TG Therapeutics by 3.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 144,236 shares of the biopharmaceutical company’s stock worth $1,897,000 after buying an additional 5,165 shares during the last quarter. Swiss National Bank raised its holdings in TG Therapeutics by 7.7% during the first quarter. Swiss National Bank now owns 96,200 shares of the biopharmaceutical company’s stock worth $1,366,000 after buying an additional 6,900 shares during the last quarter. Finally, MetLife Investment Advisors LLC raised its holdings in TG Therapeutics by 35.2% during the second quarter. MetLife Investment Advisors LLC now owns 28,284 shares of the biopharmaceutical company’s stock worth $372,000 after buying an additional 7,358 shares during the last quarter. Hedge funds and other institutional investors own 48.99% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Recommended Story: How to Invest in Growth Stocks

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.